Skip to main content

Advertisement

SpringerLink
Log in

Oxaliplatin combined with S-1 capsule in the treatment of 62 cases with advanced gastric cancer

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

The aim of this study was to evaluate the efficacy and safety profile of DeFazio (S-1) combined with oxaliplatin against unresectable advanced or metastatic gastric cancer.

Methods

Oxaliplatin was given intravenously at 130 mg/m2 for 2 h on d1 and S-1 was administered bid. at 80 mg/m2/day on d1-14 followed by a 7-day rest during the 3-week schedule.

Results

All 62 patients were assessed for efficacy and adverse events. The response and disease control rates were 47.3% and 80.8%, respectively. The median time to progression was 7.8 months, and the median overall survival was 11.6 months. The grade 3/4 adverse events were hematological toxicities, including neutropenia (11.3%), thrombocytopenia (9.7%) and gastrointestinal reactions (6.5%).

Conclusion

The SOX regimen (oxaliplatin, 130 mg/m2 d1; S-1, 80 mg/m2/day, bid. d1-14, q3w) provide a favorable efficacy and safety profile in patients with advanced gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mizoshita T, Kataoka H, Kubota E, et al. Gastricphenotype signetring cell carcinoma of the stomach with multiple bone metastasis effectively treated with sequential meth-otrexate and 5-fluorouracil. Int J Clin Oncol, 2008, 13:373–376.

    Article  PubMed  Google Scholar 

  2. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol, 2008, 43: 256–264.

    Article  CAS  PubMed  Google Scholar 

  3. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 2006, 24: 4991–4997.

    Article  PubMed  Google Scholar 

  4. Chen JS, Rau KM, Chen YY, et al. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer. Cancer Chemother Pharmacol, 2009, 63: 819–825

    Article  CAS  PubMed  Google Scholar 

  5. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology, 2002, 16: 89–96.

    PubMed  Google Scholar 

  6. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oneologist, 2002, 7: 288–323.

    Article  CAS  Google Scholar 

  7. Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotechnol, 2000, 1: 137–164.

    Article  CAS  PubMed  Google Scholar 

  8. Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity 0f 5-fluorouracil by two biochemical modulators. Anticancer Drugs, 1996, 7: 548–557.

    Article  CAS  PubMed  Google Scholar 

  9. Sato A, Ito T, Tomita T, et al. Chemotherapy of gastric cancer—a review of clinical trials in Japan. Gan To Kagaku Ryoho, 2002, 29: 1522–1531.

    PubMed  Google Scholar 

  10. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancel Oncol. 2008, 9: 215–221.

    Article  CAS  Google Scholar 

  11. Boku N, Gastrointestinal Oncology Study Group of Japan Clinical Oncology. Chemotherapy for metastatic disease: review from JCOG trials. Int J Clin Oncol, 2008, 13: 196–200.

    Article  CAS  PubMed  Google Scholar 

  12. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol, 2008, 26: 1435–1442.

    Article  CAS  PubMed  Google Scholar 

  13. Kim KH, Park YS, Chang MH, et al. A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer. Cancer Chemother Pharmacol, 2009, 64: 347–353.

    Article  CAS  PubMed  Google Scholar 

  14. Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol, 2010, 21: 1001–1005.

    Article  CAS  PubMed  Google Scholar 

  15. Oh SY, Kwon HC, Jeong SH, et al. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Invest New Drugs, 2012, 30: 350–356.

    Article  CAS  PubMed  Google Scholar 

  16. Liu B, Ying J, Luo C, et al. S-1 combined with oxaliplatin as first line chemotherapy for Chinese advanced gastric cancer patients. Hepatogastroemterology, 2012, 59: 649–653.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Qingdao Cancer Hospital, Qingdao, 266042, China

    Wenhui Li & Qiuju Lin

Authors
  1. Wenhui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiuju Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wenhui Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, W., Lin, Q. Oxaliplatin combined with S-1 capsule in the treatment of 62 cases with advanced gastric cancer. Chin. -Ger. J. Clin. Oncol. 12, 416–418 (2013). https://doi.org/10.1007/s10330-013-1191-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-013-1191-1

Key words

Search

Navigation